"The authors are concluding that BWSTT and RAST do not have the evidence to support their use in MS rehabilitation and should only be provided in the context of a clinical trial. A similar stance to what I have taken in relation to CCSVI. It is unethical to expose MS'ers to expensive therapies that may not work or worse still cause harm."